Eriksen EF, Díez-Pérez A, Boonen S (January 2014). “Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review”. 《Bone》 58: 126–35. doi:10.1016/j.bone.2013.09.023. PMID24120384.
Serrano AJ, Begoña L, Anitua E, Cobos R, Orive G (December 2013). “Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis”. 《Gynecol. Endocrinol.》 29 (12): 1005–14. doi:10.3109/09513590.2013.813468. PMID24063695. S2CID20163452.
“Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society”. 《Menopause》 17 (1): 25–54; quiz 55–6. 2010. doi:10.1097/gme.0b013e3181c617e6. PMID20061894. S2CID7980731.
Compston J, Bowring C, Cooper A 외 (August 2013). “Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013”. 《Maturitas》 75 (4): 392–6. doi:10.1016/j.maturitas.2013.05.013. PMID23810490.
Zhu M, Liang R, Pan LH 외 (February 2013). “Zoledronate for metastatic bone disease and pain: a meta-analysis of randomized clinical trials”. 《Pain Med》 14 (2): 257–64. doi:10.1111/pme.12016. PMID23279447.
Zhu J, Zheng Y, Zhou Z (June 2013). “Oral adjuvant clodronate therapy could improve overall survival in early breast cancer: results from an updated systematic review and meta-analysis”. 《Eur. J. Cancer》 49 (9): 2086–92. doi:10.1016/j.ejca.2013.01.021. PMID23452992.
Van Acker, HH; Anguille, S; Willemen, Y; Smits, EL; Van Tendeloo, VF (2015년 11월 23일). “Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials.”. 《Pharmacology & Therapeutics》 158: 24–40. doi:10.1016/j.pharmthera.2015.11.008. PMID26617219.
Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ (May 2008). “Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells”. 《Bone》 42 (5): 848–860. doi:10.1016/j.bone.2007.12.225. PMID18325866.
Frith J, Mönkkönen J, Blackburn G, Russell R, Rogers M (1997). “Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro”. 《J Bone Miner Res》 12 (9): 1358–67. doi:10.1359/jbmr.1997.12.9.1358. PMID9286751.
Van Beek E, Löwik C, van der Pluijm G, Papapoulos S (1999). “The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates”. 《J Bone Miner Res》 14 (5): 722–9. doi:10.1359/jbmr.1999.14.5.722. PMID10320520. S2CID20316713.
Uzzan, B 외 (2007). “Effects of statins on bone mineral density: a meta-analysis of clinical studies”. 《Bone》 40 (6): 1581–7. doi:10.1016/j.bone.2007.02.019. PMID17409043.
Eriksen EF, Díez-Pérez A, Boonen S (January 2014). “Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review”. 《Bone》 58: 126–35. doi:10.1016/j.bone.2013.09.023. PMID24120384.
Serrano AJ, Begoña L, Anitua E, Cobos R, Orive G (December 2013). “Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis”. 《Gynecol. Endocrinol.》 29 (12): 1005–14. doi:10.3109/09513590.2013.813468. PMID24063695. S2CID20163452.
Gauthier, K; Bai, A; Perras, C; Cunningham, J; Ahuja, T; Richter, T; Kovacs, C (February 2012). “Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis: Clinical Effectiveness and Harms”. 《Rapid Response Report: Systematic Review》. PMID24278999.
“Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society”. 《Menopause》 17 (1): 25–54; quiz 55–6. 2010. doi:10.1097/gme.0b013e3181c617e6. PMID20061894. S2CID7980731.
Hauk L (August 2013). “ACOG releases practice bulletin on osteoporosis”. 《Am Fam Physician》 88 (4): 269–75. PMID23944732.
Compston J, Bowring C, Cooper A 외 (August 2013). “Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013”. 《Maturitas》 75 (4): 392–6. doi:10.1016/j.maturitas.2013.05.013. PMID23810490.
Zhu M, Liang R, Pan LH 외 (February 2013). “Zoledronate for metastatic bone disease and pain: a meta-analysis of randomized clinical trials”. 《Pain Med》 14 (2): 257–64. doi:10.1111/pme.12016. PMID23279447.
Zhu J, Zheng Y, Zhou Z (June 2013). “Oral adjuvant clodronate therapy could improve overall survival in early breast cancer: results from an updated systematic review and meta-analysis”. 《Eur. J. Cancer》 49 (9): 2086–92. doi:10.1016/j.ejca.2013.01.021. PMID23452992.
Van Acker, HH; Anguille, S; Willemen, Y; Smits, EL; Van Tendeloo, VF (2015년 11월 23일). “Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials.”. 《Pharmacology & Therapeutics》 158: 24–40. doi:10.1016/j.pharmthera.2015.11.008. PMID26617219.
Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ (May 2008). “Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells”. 《Bone》 42 (5): 848–860. doi:10.1016/j.bone.2007.12.225. PMID18325866.
Frith J, Mönkkönen J, Blackburn G, Russell R, Rogers M (1997). “Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro”. 《J Bone Miner Res》 12 (9): 1358–67. doi:10.1359/jbmr.1997.12.9.1358. PMID9286751.
Van Beek E, Löwik C, van der Pluijm G, Papapoulos S (1999). “The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates”. 《J Bone Miner Res》 14 (5): 722–9. doi:10.1359/jbmr.1999.14.5.722. PMID10320520. S2CID20316713.
Uzzan, B 외 (2007). “Effects of statins on bone mineral density: a meta-analysis of clinical studies”. 《Bone》 40 (6): 1581–7. doi:10.1016/j.bone.2007.02.019. PMID17409043.
Serrano AJ, Begoña L, Anitua E, Cobos R, Orive G (December 2013). “Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis”. 《Gynecol. Endocrinol.》 29 (12): 1005–14. doi:10.3109/09513590.2013.813468. PMID24063695. S2CID20163452.
“Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society”. 《Menopause》 17 (1): 25–54; quiz 55–6. 2010. doi:10.1097/gme.0b013e3181c617e6. PMID20061894. S2CID7980731.
Van Beek E, Löwik C, van der Pluijm G, Papapoulos S (1999). “The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates”. 《J Bone Miner Res》 14 (5): 722–9. doi:10.1359/jbmr.1999.14.5.722. PMID10320520. S2CID20316713.